ICON reports Full-Year 2009 EPS growth of 18% and announces Revenue and EPS Guidance for 2010
Mr. Bob Scott-Edwards has retired from the position of President, ICON Central Laboratories. Mr. Tom O’Leary, previously Senior Vice President and Global Head of Data Management, ICON Clinical Research, has succeeded Mr. Scott-Edwards.
ICON has expanded its European Central Laboratory in Dublin. The newly-designed 41,000 sq ft (3,800m²) facility, which is three times the size of the previous laboratory, provides centralised testing and site support services to clinical investigators in over 70 countries throughout Europe, Middle East and Africa.
The unit is the first deliverable from a collaborative agreement between ICON and the Central Manchester University Hospitals Foundation (CMFT) to develop purpose-built translational medicine facilities on the newly-developed Manchester Royal Infirmary (MRI) campus.
ICON has signed an extension to its strategic agreement with Eli Lilly and Company to manage the company’s clinical data management outside the US. This extension means that ICON will now also manage Lilly’s needs in Japan in addition to those in Europe, Canada, Latin America, Australia and Asia.
a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for its third quarter ended September 30, 2009.
ICON has announced the company’s Bioanalytical Sciences leadership team, following the acquisitions of Prevalere Life Sciences and Veeda Laboratories Ltd.
ICON Development Solutions division has released a new version of NONMEM®, ICON’s non-linear, mixed effects modelling tool for Population Pharmacokinetic/Pharmacodynamic (PK/PD) data analysis.
ICON’s bioanalytical laboratory in Manchester, UK, has received GCP and GLP accreditation from the MHRA (Medicines and Healthcare products Regulatory Agency).